## LAW OFFICES OF LEONA L. LAUDER

INTELLECTUAL PROPERTY - SPECIALIZING IN BIOTECHNOLOGICAL AND CHEMICAL PATENTS 465 CALIFORNIA STREET, SUITE 450 SAN FRANCISCO, CALIFORNIA 94104-1840 TELEPHONE (415) 981-2034 FAX (415) 981-0332

RECEIVED **CENTRAL FAX CENTER** 

### FACSIMILE MESSAGE

MAY 1 8 2005

Examiner	Anne	L.	Holleran
		_	

Group Art Unit: 1642

TO USPTO

703-872-9306 FAX NO.:

FROM:

Leona L. Lauder

DATE

May 18, 2005

NO. OF PAGES FOLLOWING:

IMPORTANT NOTICE

The information contained in this facsimile message may include attorney-client privileged and confidential information intended only for the use of the individual or entity named above and others who have been specifically authorized to receive it. If you are not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone (415-981-2034) and return the original transmission to us by mail without making a copy. Thank you.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant :

Bruce M. Bowman

Group: 1600

Serial No.:

09/480,389

Group Art Unit: 1642

Filed

January 11, 2000

Examiner: A. Holleran

For

Immunoassays to Detect Diseases or Disease Susceptibility Traits

Response under 37 CFR 1.116 Expedited Procedure -Examining Group 1600

#### Certification of Facsimile Transmission

I hereby certify that this paper and the documents referred to as attached therein are being facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Denise Ortega

Name

RECEIVED CENTRAL FAX CENTER

May 18, 2005

Date

MAY 18 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Bruce M. Bowman Applicant :

Group: 1600

09/480,389 Serial No.:

Group Art Unit: 1642

Filed

January 11, 2000

Examiner: A. Holleran

For

Immunoassays to Detect Diseases or Disease

Susceptibility Traits

#### AMENDMENT TRANSMITTAL

MAIL STOP AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Transmitted herewith is a response to the final office action mailed from the U.S. Patent and Trademark Office on March 18, 2005

No fee should be required for the accompanying response. The fee for claims has been calculated as shown below:

		_				
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL	27	MINUS	50	0	X \$ 50	\$ 0.00
INDEP.	1	MINUS	3	0	X \$ 200	\$ 0.00

[ ] FIRST PRESENTATION OF MULTIPLE DEP. CLAIM + \$360 \$ 0.00

However, should any additional fees be determined to be necessary in connection with this paper, Applicants respectfully request that any such additional fees be charged to Deposit Account No. 12-0615.

Respectfully submitted,

Leona L. Lauder

Attorney for Applicants Registration No. 30,863

Dated: May 18, 2005

#### RECEIVED CENTRAL FAX CENTER

MAY 1 8 2005

Response under 37 CFR 1.116 Expedited Procedure – Examining Group 1600

#### Certification of Facsimile Transmission

I hereby certify that this paper and the documents referred to as attached therein are being facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Denise Ortega Name

May 18, 2005
Date:

Signature

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

: Bruce M. Boman

Group: 1600

Serial No

.: 09/480,389

Group Art Unit: 1642

Filed

: January 11, 2000

Examiner: Anne L. Holleran

For

: Immunoassays to Detect Diseases or Disease Susceptibility Traits

# AMENDMENT AFTER FINAL UNDER 37 CFR 1.116

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This Amendment to the above-identified application is in response to the Final Office Action mailed from the U.S. Patent and Trademark Office (PTO) on March 18, 2005 and is being made within the two month period from the mailing of the Final Office Action. Applicants respectfully request that this <u>Amendment After Final</u> be

entered in accordance with 37 CFR § 116(a) and with the Manual of Patent Examining Procedure (MPEP) §§ 714.12 and 714.13.

Applicants respectfully submit that the instant <u>Amendment After Final</u> does not raise any new issues and presents the rejected claims "in condition for allowance." [MPEP § 714.12.] Detailed reasoning supporting the absence of any new issues and the allowability of the claims as amended follows below after the <u>Remarks</u> section, which section shows support in the Specification for the claim amendments. Thus, Applicants respectfully request that this <u>Amendment After Final</u> be entered, and that the claims as amended be allowed.